Skip to main content
    S

    Summit Therapeutics PLC (SMMT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $16.33
    +2.14 (+15.08%)

    Market Cap: $12.90B

    Last updated: Nov 06, 2026 at 4:38 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    50%(17/34)
    Avg Surprise
    -453.54%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Dec 31, 2026
    EPS Consensus$-0.22
    Range$-0.60 - $0.12
    11 analysts
    Revenue Consensus
    $3M
    Range$-94640 - $11M
    15 analysts
    Last 12 of 37 reported quarters and 1 upcoming estimate
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Dec 26EST
    		-$-0.22$-0.60 - $0.12--11--
    Sep 26
    Reported Nov 4
    		$-0.26$-0.28$-0.32 - $-0.11+7.14%Beat12
    1
    7
    30d
    		-13.0%
    Jun 26
    Reported Jul 23
    		$-0.28$-0.26$-0.34 - $-0.13-7.69%Miss11
    2
    2
    30d
    		-133.3%
    Mar 26
    Reported Apr 30
    		$-0.18$-0.12$-0.25 - $-0.10-45.19%Miss10
    0
    3
    30d
    		-161.0%
    Dec 25
    Reported Feb 23
    		$-0.21$-0.01$-0.24 - $0.75-2000.00%Miss11
    3
    0
    30d
    		-250.0%
    Sep 25
    Reported Oct 20
    		$-0.23$-0.04$-0.55 - $0.85-475.00%Miss11
    No revisions (30d)
    		-283.3%
    Jun 25
    Reported Aug 11
    		$-0.12$-0.09$-0.10 - $-0.08-33.33%Miss7
    1
    1
    30d
    		-71.4%
    Mar 25
    Reported May 1
    		$-0.07$-0.07$-0.07 - $-0.06+0.73%Beat6
    1
    0
    30d
    		-35.4%
    Dec 24
    Reported Feb 24
    		$-0.06$-0.06$-0.07 - $-0.06+0.00%Beat4
    0
    2
    30d
    		-50.0%
    Sep 24
    Reported Oct 30
    		$-0.06$-0.05$-0.05 - $-0.04-20.00%Miss3
    No revisions (30d)
    		-100.0%
    Jun 24
    Reported Aug 6
    		$-0.07$-0.05$-0.05 - $-0.05-40.00%Miss2
    No revisions (30d)
    		-250.0%
    Mar 24
    Reported May 1
    		$-0.05$-0.05$-0.05 - $-0.05+0.00%Beat1
    No revisions (30d)
    		+96.5%
    Dec 23
    Reported Feb 20
    		$-0.04$-0.05$-0.05 - $-0.05+20.00%Beat0
    No revisions (30d)
    		+42.9%

    Key Metrics

    Valuation
    P/E Ratio-15.46EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-192.50%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio5.99xQuick Ratio5.99x
    Trading Statistics
    Beta-1.52Avg Volume4.95M
    52-Week High$29.2352-Week Low$12.07

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$15.51
    SMA 20$15.57
    SMA 50$16.25
    SMA 200$16.14
    EMA 10$15.60
    EMA 20$15.73
    EMA 50$15.79
    EMA 200$16.54

    MACD

    Line: -0.17Signal: -0.19Hist: 0.02

    ADX

    ADX: 13.5+DI: 16.2-DI: 22.8

    Aroon & PSAR

    Aroon Up12.0
    Aroon Down96.0
    PSAR$16.38

    Bollinger Bands

    Upper Band$16.97
    Lower Band$14.18
    %B Position1792%(Upper)
    Band Width0.77

    RSI (14-Day)

    Neutral
    52.6

    Momentum Oscillators

    Stoch %K58.1
    Stoch %D54.6
    Williams %R-9.2
    ROC (10d)5.6%
    Momentum0.86
    CCI (20d)33.2
    MFI (14d)62.0

    Volatility Measures

    ATR (14d)$1.16(7.1%)
    StdDev (20d)0.70
    Hist Vol100.5%(High)

    Volume Flow

    VWAP$15.80
    OBV35.7M
    AD Line-95.6M
    CMF (20d)-0.020

    Volume Metrics

    Avg Vol (20d)4.9M
    Vol Ratio1.2x
    VWMA (20d)$15.57

    Pivot Points

    R3$17.43
    R2$16.78
    R1$15.48
    Pivot Point$14.83
    S1$13.53
    S2$12.88
    S3$11.58

    Advanced Oscillators

    TSI-4.12
    Ultimate Osc51.6
    KST-74.14

    Financial Data

    QuarterSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total RevenueN/A$0$0$0$0$0$0$0$0$0$0$-235,000
    Cost of RevenueN/AN/A$44,000$4,355N/A$37,000$25,000$14.94M$19,999$20,000$27,000$605,000
    Gross ProfitN/AN/A$-44,000$-4,355N/A$-37,000$-25,000$-14,940,000$-19,999$-20,000$-27,000$-840,000
    Operating Expenses$214.61M$220.50M$195.21M$224.88M$234.21M$234.21M$51.75M$52.41M$43.66M$47.16M$33.59M$28.40M
    R&D$169.13M$157.73M$132.62M$147.29M$131.10M$131.10M$39.68M$41.04M$28.22M$36.23M$24.47M$19.46M
    SG&A$45.48M$62.76M$62.59M$77.58M$103.11M$103.11M$12.06M$11.53M$15.25M$10.93M$9.13M$9.08M
    Operating IncomeN/A$-220,496,000$-195,212,000$-224,875,000$-234,211,000$-234,211,000$-51,747,353$-52,408,526$-43,663,825$-47,161,220$-33,592,010$-28,404,210
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$2.38M
    Interest Expense$0$0$0$0$0$0$0$9,000$2.46M$3.10M$3.12M$2.90M
    Income Before Tax$-208,385,000$-215,700,000$-189,424,000$-219,122,000$-231,793,000$-231,793,000$-48,699,065$-48,885,284$-42,075,179$-47,768,761$-34,451,048$-28,684,251
    Income Tax Expense$0$0$0$0$0$0$0$24,000$264,000$-159,000$3.12M$-199,000
    Net Income$-208,385,000$-215,700,000$-189,424,000$-219,172,000$-231,793,000$-231,793,000$-48,699,065$-48,885,284$-42,075,179$-47,768,761$-34,451,048$-28,684,251
    EBITDAN/A$-215,654,000$-189,380,000$-219,080,000$-231,751,000$-231,751,000$-48,674,065$-48,854,284$-39,600,179$-35,269,632$-31,303,048$-25,182,251
    EBITN/A$-215,700,000$-189,424,000$-219,122,000$-231,793,000$-231,793,000$-48,699,065$-48,876,284$-39,620,179$-35,289,632$-31,330,048$-25,787,251
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SMMT

    News

    Summit Therapeutics Q3 Results: Adj. EPS of $(0.20) beats estimates

    Summit Therapeutics reported an adjusted loss per share of $(0.20) for the third quarter, which surpassed analyst estimates of $(0.28). While this represents a 28.57% improvement over expected figures...

    scanx.trade•11/4/26•Neutral

    AstraZeneca invested $2B in Summit Therapeutics (SMMT), which reported a narrower Q3 loss.

    Summit Therapeutics reported a narrower net loss of $208.4 million in Q3 2026, down from $231.8 million a year earlier...

    Stock Titan•11/4/26•Neutral

    Form 8-K Summit Therapeutics Inc. For: Nov 04

    Summit Therapeutics Inc. filed a Form 8-K on November 4, 2026, announcing its third-quarter 2026 financial results and operational progress. The company's stockholders also approved an amendment to increase...

    StreetInsider•11/4/26•Neutral

    Form 8K Summit Therapeutics PLC ADR For: 4 November By Investing.com

    This article reports on the filing of a Form 8K by Summit Therapeutics PLC ADR on November 4, 2026. The financial instrument SMMT is mentioned with a 2.34% increase. The content appears to be a brief announcement...

    Investing.com Canada•11/4/26•Neutral

    Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026

    Summit Therapeutics reported a GAAP net loss of $208.4 million, or $(0.26) per share, for the third quarter of 2026...

    Quantisnow•11/4/26•Somewhat-Bullish

    SMMT Valuation and Fair Value

    P/E
    -15.5x
    Forward P/E
    3.7x
    PEG
    0.0x
    P/B
    23.1x
    See GNG's fair value

    SMMT Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -192.5%

    SMMT Competitors

    CompanyTicker
    BrightSpring Health Services, Inc. Common StockBTSG
    Tempus AI, Inc. Class A Common StockTEM
    Baxter International IncBAX
    Penumbra IncPEN
    Smith & Nephew SNATS IncSNN
    Dr. Reddy’s Laboratories Ltd ADRRDY
    Encompass Health CorpEHC
    DaVita HealthCare Partners IncDVA

    Sector: Healthcare

    SMMT Analyst Ratings

    Consensus
    Buy
    Analysts
    17
    Strong Buy
    1
    Buy
    10
    Hold
    6
    Sell
    0
    Strong Sell
    0

    SMMT Bull Case vs Bear Case

    Bull case

    • 64.7% of SMMT's analyst ratings are Buy or Strong Buy.

    Bear case

    • SMMT beat EPS estimates in 25.0% of its last 8 reported quarters.
    • SMMT's quarterly revenue changed -100.0% year over year.

    SMMT Earnings: Beat Rate and Next Report

    Beat rate
    2 of 8 quarters (25.0%)
    Average surprise
    -319.2%
    EPS estimate (fiscal period ending Dec 31, 2026)
    $-0.22

    SMMT Earnings Date

    SMMT reports Feb 22, 2027, before the open. The date is confirmed.

    SMMT Earnings Call

    The latest SMMT earnings call transcript on file is labeled 2026Q2.

    Read the 2026Q2 transcript

    SMMT ETF Holders

    GNG tracks 19 ETFs that hold SMMT. The largest weights:

    1. abrdn Healthcare Investors (HQH), 0.71% of the fund
    2. State Street SPDR S&P Biotech ETF (XBI), 0.56% of the fund
    3. Invesco NASDAQ Next Gen 100 ETF (QQQJ), 0.35% of the fund
    4. BlackRock Health Sciences Trust (BME), 0.29% of the fund
    5. iShares Biotechnology ETF (IBB), 0.16% of the fund
    Open the ETF Stock Exposure tool for SMMT

    See insider activity

    Frequently Asked Questions About SMMT

    When does SMMT report earnings?

    Summit Therapeutics PLC (SMMT) is confirmed to report earnings on Feb 22, 2027.

    Does SMMT pay dividends?

    Summit Therapeutics PLC (SMMT) does not currently pay a regular dividend.

    What is SMMT's market cap?

    Summit Therapeutics PLC (SMMT) has a market capitalization of $12.90B with a current stock price of $16.33.

    Related stocks

    Sector: Healthcare

    All stocks starting with S

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In